文献速递腹部CT

局部晚期与交界可切除胰腺癌FOLFIRINOX治疗后手术:CT上肿瘤衰减增加与R0切除相关

Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
PubMed 文献 · Eur Radiol · 2018-04-20

回顾性纳入59例FOLFIRINOX诱导治疗后手术探查的局部晚期或交界可切除胰腺导管腺癌患者,两名胰腺放射科医师盲法评估CT可切除性。CT预测可切除性的敏感度为86%、特异度为29%;仅R0切除组出现各期肿瘤衰减显著增加,作者认为CT上肿瘤衰减增加可能可靠预测R0切除。

要点

  • FOLFIRINOX治疗后CT预测可切除性敏感度86%但特异度仅29%。
  • 仅R0切除组出现动脉期与静脉期肿瘤衰减显著增加。
  • CT上肿瘤衰减增加可能可靠预测R0切除。

核心结论

  • FOLFIRINOX新辅助治疗后,CT预测可切除性敏感度可接受但特异度低;CT上观察到肿瘤衰减增加可能可靠预测R0切除。

研究设计与样本

  • 回顾性纳入59例FOLFIRINOX诱导治疗后接受手术探查的局部晚期或交界可切除胰腺导管腺癌患者。
  • 两名胰腺放射科医师盲法审阅CT,评估化疗反应与可切除性,以最终手术病理R0为参考。
  • 患者分为R0切除组(A组)与未切除/R1切除组(B组)进行比较。

关键影像表现/征象

  • 两组最长肿瘤径均显著缩小:A组从32 mm(95%CI 15-55)降至21 mm(10-44),B组从34 mm(18-70)降至26 mm(7-60),p<0.05。
  • 仅R0切除组出现所有期相肿瘤衰减显著增加:动脉期从52 HU(26-75)升至65 HU(35-92),p<0.001;静脉期从62 HU(36-96)升至78 HU(40-120),p=0.001。

诊断标准与关键数值

  • 盲法影像评估将19例(32%)定义为不可切除、33例(56%)为交界可切除、7例(12%)为可切除。
  • 手术探查中27%不可切除,73%接受手术切除,R0率为70%。
  • CT预测可切除性的敏感度为86%、特异度为29%。

临床应用与阅片要点

  • FOLFIRINOX治疗后评估可切除性时,CT敏感度可接受但特异度低,需注意假阳性可能。
  • 阅片时关注肿瘤衰减的变化,其增加可能提示R0切除。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess factors associated with radical resection (R0) of pancreatic ductal adenocarcinoma (PDAC) after induction treatment with FOLFIRINOX.

METHODS: Patients with either locally advanced (LA) and borderline resectable (BR) PDAC undergoing surgical exploration after FOLFIRINOX were retrospectively enrolled. Two pancreatic radiologists reviewed the CT blinded to the final outcome and assessed chemotherapy response and resectability. Patients were then divided into R0 resected (group A) and not resected/R1 resected (group B), which were compared.

RESULTS: Of 59 patients included, 19 were defined as unresectable (32%), 33 borderline resectable (56%) and 7 resectable (12%) during the blind radiological evaluation after FOLFIRINOX. Once in a surgical setting, 27% were non-resectable, whereas 73% received surgical resection with a 70% R0 rate. Consequent sensitivity and specificity were 86% and 29%. At imaging review, significant decreases in longest tumour dimension were observed in both groups: from 32 mm (95% CI 15-55) to 21 (10-44) in group A and from 34 (18-70) to 26 (7-60) in group B, p < 0.05. However, a significant increase in tumour attenuation in all phases was only observed for R0 resected, from 52 HU (26-75) to 65 (35-92) in arterial phase (p < 0.001) and from 62 (36-96) to 78 (40-120) in the venous (p = 0.001).

CONCLUSION: After neoadjuvant FOLFIRINOX, CT predicted resectability with acceptable sensitivity but low specificity. The observation of increased tumour attenuation at CT scan after FOLFIRINOX treatment might represent a reliable predictor of R0 resection.

KEY POINTS: • CT drives the assessment of PDAC resectability after FOLFIRINOX • CT predicts resectability with acceptable sensitivity but low specificity • Significant increase in tumour attenuation was only observed for R0 resected PDAC • Tumour attenuation after FOLFIRINOX represents a reliable predictor of R0 resection.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Marchegiani G, Todaro V, Boninsegna E, et al. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection. Eur Radiol. 2018. PMID: 29679211. doi:10.1007/s00330-018-5410-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。